ODDO BHF Initiates Coverage of Carvolix with Strong Outlook

On July 29, 2026, Carvolix, previously known as Affluent Medical, announced that ODDO BHF has initiated coverage of its shares with an Outperform rating. The French medical technology company, known for its AI-driven mini-robots and biomimetic implants, received a price target of €10.50 from ODDO BHF, suggesting an 89% upside potential relative to its closing share price on July 28, 2026.

The research report, titled “A multi-specialty interventional platform,” was published on July 28, 2026. This development expands Carvolix's equity research coverage, adding to existing analysts from firms like Allinvest Securities, Kepler Cheuvreux, and Portzamparc Groupe BNP Paribas.

The Outperform rating and price target are exclusive analyses from ODDO BHF. Importantly, this communication is not an offer for securities transactions.